1. Home
  2. FRES vs MYNZ Comparison

FRES vs MYNZ Comparison

Compare FRES & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FRES
  • MYNZ
  • Stock Information
  • Founded
  • FRES 2010
  • MYNZ 2021
  • Country
  • FRES United States
  • MYNZ Germany
  • Employees
  • FRES N/A
  • MYNZ N/A
  • Industry
  • FRES Medical Specialities
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • FRES Health Care
  • MYNZ Health Care
  • Exchange
  • FRES Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • FRES 70.9M
  • MYNZ 9.8M
  • IPO Year
  • FRES 2020
  • MYNZ 2021
  • Fundamental
  • Price
  • FRES $2.96
  • MYNZ $0.48
  • Analyst Decision
  • FRES
  • MYNZ Buy
  • Analyst Count
  • FRES 0
  • MYNZ 2
  • Target Price
  • FRES N/A
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • FRES 10.1K
  • MYNZ 1.3M
  • Earning Date
  • FRES 07-23-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • FRES N/A
  • MYNZ N/A
  • EPS Growth
  • FRES N/A
  • MYNZ N/A
  • EPS
  • FRES N/A
  • MYNZ N/A
  • Revenue
  • FRES $2,345,304.00
  • MYNZ $895,479.00
  • Revenue This Year
  • FRES N/A
  • MYNZ $67.40
  • Revenue Next Year
  • FRES N/A
  • MYNZ $191.13
  • P/E Ratio
  • FRES N/A
  • MYNZ N/A
  • Revenue Growth
  • FRES N/A
  • MYNZ 69.00
  • 52 Week Low
  • FRES $2.50
  • MYNZ $0.32
  • 52 Week High
  • FRES $41.80
  • MYNZ $4.90
  • Technical
  • Relative Strength Index (RSI)
  • FRES 40.27
  • MYNZ 47.27
  • Support Level
  • FRES $2.81
  • MYNZ $0.39
  • Resistance Level
  • FRES $3.70
  • MYNZ $0.56
  • Average True Range (ATR)
  • FRES 0.40
  • MYNZ 0.09
  • MACD
  • FRES 0.00
  • MYNZ 0.02
  • Stochastic Oscillator
  • FRES 35.94
  • MYNZ 66.45

About FRES Fresh2 Group Limited

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: